Corporate Magazine 2012 - Boehringer Ingelheim

usiness year 2012group management reportNet sales by region(in millions of EUR) 2012 2011 ChangeAmericas 5,556 4,831 15.0%Europe 2,822 2,671 5.7%Asia, Australasia, Africa (AAA) 2,815 2,380 18.3%Consumer Health CareOur business with non-prescription drugs also developedpositively last year. With an encouraging 7.8% increaseon the previous year (4.7% after adjustment forexchange rate effects), sales of EUR 1,505 million weregenerated in 2012.buscopan®, dulcolax®, mucosolvan® and pharmaton®were again our best-selling non-prescription productsin the last financial year, with revenues of more thanEUR 100 million each. buscopan® again posted thehighest revenues (EUR 212 million) and the highest growthrate (+ 17.8%) compared with the previous year. In addition,our products bisolvon® and zantac® broke theEUR 100 million sales barrier for the first time in 2012.Net sales (in millions of EUR) 2012 2011 Changebuscopan® 212 180 17.8%dulcolax® 193 171 12.9%mucosolvan® 166 160 3.8%pharmaton® 136 137 — 0.7%In regional terms, the Europe region accounted for thehighest proportion of total sales in the Consumer HealthCare business at EUR 557 million (+ 3.2% compared with2011). Germany, which is the most important sales marketin Europe, enjoyed a solid 3.7% increase in sales toEUR 139 million. The highest growth rate in the 2012financial year was in the AAA region, where sales increasedby 14.1% to EUR 486 million, and the Americaswas the second strongest region in the Consumer HealthCare business. The positive development of this region isdominated by the key Japanese market, where we achievedsales of EUR 294 million (+ 7.3%). In the Americas region,sales were up 7.4% to EUR 462 million, mainly driven bysales growing by 11.6% to EUR 162 million in the mostimportant market, the USA, as well as high growth ratesin some South American countries.Industrial CustomersThe Industrial Customer business encompasses our thirdpartybusiness in the field of Pharmaceutical Productionand our contract manufacturing business for PharmaChemicals. The biopharmaceuticals contract manufacturingbusiness, allocated to the Industrial Customerssegment until 2011, was integrated into the new Biopharmaceuticalsbusiness unit at the start of 2012.With revenues of EUR 162 million, the Industrial Customerbusiness continued to decline in a challenging marketenvironment (– 9.0% compared with the previous year).BiopharmaceuticalsSince the last financial year, Boehringer Ingelheim’s operatingactivities have been divided into Human Pharmaceuticals,Biopharmaceuticals and Animal Health.The new Biopharmaceuticals business unit consists ofthe contract manufacturing business, biosimilars and researchand development of new biological active ingredients.The contract manufacturing business has beengiven its own identity with the brand name BoehringerIngelheim BioXcellence. Revenues were only generatedfrom the contract manufacturing business in 2012. TheBiopharmaceuticals business posted annual sales ofEUR 549 million, an increase of 5.8%.Animal HealthIn its worldwide business with animal health products,Boehringer Ingelheim significantly increased its revenuesagain last year. With growth of 8.8% comparedwith 2011 (3.8% after adjustment for exchange rate effects),we broke the EUR 1 billion sales barrier for thefirst time here (EUR 1,062 million). Porcine vaccineswere again the most important growth driver, performingstrongly in this highly contested market. The bestsellingand fastest-growing product, ingelvac circoflex®,generated revenues of EUR 279 million, up 8.6% on 2011.In addition to success in the livestock business, ourproducts in the companion animal segment also devel-Net assets, financial position and results from operations33